Antidepressants Are No Longer Just About Serotonin
For several decades, the treatment of depression has been organized around a relatively simple biological idea: that mood disorders are primarily linked to disturbances in monoamine neurotransmitters, especially serotonin. This model, often referred to as the monoamine hypothesis, shaped not only pharmacology, but also how depression was explained to patients. Selective serotonin reuptake inhibitors and related drugs became the standard of care (Lexapro vs. Zoloft, Wellbutrin & More: Choosing the Right Antidepressant for You), and the broader cultural narrative followed. Depression was commonly described as a “chemical imbalance,” and treatment was framed as a way of restoring that balance. This framework was not without merit. Serotonergic antidepressants are effective for many patients, and they remain a foundational part of clinical practice. However, over time, several limitations became increasingly difficult to ignore. A significant proportion of patients do not respond adequately to these medications. Others experience only partial improvement. Even in successful cases, the onset of therapeutic effects is often delayed, requiring weeks of continuous treatment before meaningful changes occur. These patterns raised a fundamental question: if serotonin were the central driver of depression, why would interventions targeting it be inconsistently effective and slow to act?
By the mid-2020s, the field began to shift in a more explicit way. The focus moved away from the idea of a single neurotransmitter deficit toward a broader understanding of depression as a disorder involving neural circuits, synaptic plasticity, and stress regulation systems. In this emerging view, mood is not governed by the level of one chemical, but by the dynamic functioning of interconnected brain networks. These networks can become rigid, dysregulated, or maladapted in response to stress, trauma, or other biological vulnerabilities.
This change in perspective has important implications for treatment. If depression reflects impaired adaptability at the level of brain systems, then effective interventions may need to do more than adjust neurotransmitter concentrations. They may need to restore flexibility, reorganize connectivity, and influence how the brain responds to experience over time. This is where newer approaches begin to diverge from traditional antidepressants.
By 2026, this shift is no longer theoretical. It is reflected in the mechanisms of newer treatments that act on glutamate pathways, neuroactive steroids, and other systems linked to plasticity and stress regulation. The conversation is no longer limited to serotonin and norepinephrine. Instead, it is expanding toward a more complex but also more precise understanding of how depressive states emerge and how they can be modified.
This article explores that transition. It is not about replacing one class of drugs with another, but about understanding how the biological logic of depression treatment itself is changing.
From Serotonin to Circuits. Why the Old Model Became Insufficient
The serotonin-centered model of depression was never entirely incorrect, but over time it proved incomplete. Its limitations became most visible in clinical practice, where outcomes did not always align with the expectations suggested by the theory. If depression were primarily the result of a deficit in serotonin signaling, then enhancing that signaling should reliably produce improvement. In reality, the picture has always been more complex.
One of the most persistent issues has been the delay in therapeutic effect. Selective serotonin reuptake inhibitors begin altering neurotransmitter dynamics within hours, yet patients often wait weeks before experiencing noticeable relief. This temporal gap suggests that the mechanism of improvement is not simply the immediate increase in serotonin availability. Instead, it points to downstream processes that unfold more slowly, involving changes in gene expression, synaptic strength, and neural connectivity. Another challenge has been the high rate of partial or non-response. A substantial proportion of patients do not achieve remission with first-line antidepressants, even when treatment is optimized. For some, multiple medication trials are required, and for others, symptoms persist despite adequate pharmacological intervention. These patterns indicate that serotonin modulation alone does not sufficiently address the underlying biology in many cases.
As research advanced, it became increasingly clear that depression is associated with alterations not only in neurotransmitter levels, but in the structure and function of brain networks. Regions involved in emotion regulation, such as the prefrontal cortex, amygdala, and hippocampus, show changes in connectivity and activity patterns. These alterations are not static defects, but dynamic disruptions in how different parts of the brain communicate and adapt. This led to a shift in focus toward neuroplasticity, the brain’s ability to reorganize itself in response to experience. In depression, this capacity appears to be reduced or dysregulated. Stress, one of the most consistent risk factors for depressive disorders, has been shown to impair synaptic plasticity and reduce the formation of new neural connections, particularly in regions associated with learning, memory, and emotional processing. Over time, this can lead to more rigid patterns of thought and behavior, which are difficult to modify through conventional means.
Within this framework, serotonin is no longer seen as the central driver, but as one component within a broader system. It may influence plasticity indirectly, but it does not directly target the mechanisms that restore adaptive flexibility. This helps explain why traditional antidepressants can be effective in some cases, yet insufficient in others.
The conceptual shift, then, is from a model of chemical imbalance to one of network dysfunction. Depression is increasingly understood as a condition in which the brain becomes less able to adjust, respond, and reorganize in the face of internal and external demands. This perspective opens the door to new treatment strategies that aim not only to stabilize mood, but to actively reshape neural circuits and restore adaptive capacity.
The Rise of Rapid-Acting Antidepressants: Glutamate and Neuroplasticity
The most visible sign that the field has moved beyond a serotonin-centered model is the emergence of rapid-acting antidepressants, particularly those targeting the glutamate system (Psychedelics 2.0: After MDMA’s Setback, Where Does the Field Go – and What About Psilocybin?). Among these, ketamine and its derivative esketamine have attracted attention not only for their clinical effects, but because they challenge traditional assumptions about how antidepressants work.
Unlike SSRIs, which primarily influence monoamine signaling, ketamine acts on NMDA receptors, a key component of the glutamatergic system. This system is central to excitatory signaling and plays a major role in learning, memory, and synaptic plasticity. What makes ketamine especially significant is that its effects appear to involve rapid changes in neural connectivity, rather than gradual chemical adjustment. Clinically, this difference is reflected in the speed of response. While conventional antidepressants often require weeks to take effect, ketamine can reduce symptoms within hours or days in some patients, including those with treatment-resistant depression. This suggests that its mechanism depends on immediate changes in how neurons communicate and adapt.
At a biological level, ketamine triggers processes associated with synaptogenesis, increasing glutamate activity in key brain regions and promoting the expression of proteins linked to synaptic growth. These changes are particularly relevant in areas such as the prefrontal cortex, which plays a central role in emotional regulation. This mechanism represents a shift from adjusting neurotransmitter levels to reorganizing neural circuits. Rather than stabilizing mood gradually, rapid-acting agents appear to increase the brain’s capacity for change. In this sense, they function as plasticity-enhancing interventions, helping the system move out of rigid or maladaptive states.
The concept of psychoplastogens has emerged from this line of research. These compounds enhance the brain’s ability to reorganize itself by influencing network structure and function. While ketamine is the most established example, it has also driven the development of new agents designed to replicate its effects with improved safety and accessibility.
Importantly, this approach reframes treatment goals. The aim is no longer only to correct imbalance, but to restore adaptive capacity. In patients whose neural systems have become constrained, this regained flexibility may be essential for recovery.
At the same time, these treatments raise new questions. Their effects can be rapid but sometimes transient, which means they may need to be combined with other approaches. In this context, pharmacology may act as a way to open a window of plasticity, making other interventions more effective.
The rise of glutamate-based treatments therefore represents more than a new class of drugs. It reflects a broader shift toward understanding depression as a disorder of adaptability, where recovery depends on the brain’s ability to reorganize.
Neuroactive Steroids and the Stress System – A Different Entry Point
While glutamate-based treatments highlight the role of neuroplasticity, another line of development approaches depression from a different angle, focusing on the stress response system and its regulation. This is where neuroactive steroids, such as brexanolone and zuranolone, become particularly relevant. Rather than targeting monoamines or excitatory signaling directly, these compounds act on GABA-A receptors, which are central to inhibitory signaling in the brain. This distinction is important because it shifts attention from activation to regulation and stabilization. In many forms of depression, especially those associated with chronic stress, there is evidence of dysregulation in the balance between excitation and inhibition. The brain may become persistently activated in ways that are difficult to modulate, contributing to anxiety, emotional volatility, and disrupted sleep. Neuroactive steroids appear to address this imbalance by enhancing inhibitory control, allowing neural systems to return to a more stable state.
Their mechanism is closely linked to the body’s natural response to stress. Endogenous neurosteroids fluctuate in response to hormonal changes and play a role in modulating mood and emotional reactivity. When this system is disrupted, as can occur in certain conditions, the capacity to regulate stress may be impaired. By acting on the same receptor systems, synthetic neuroactive steroids can help restore this regulatory function.
One of the most well-known applications of this approach is in postpartum depression, where rapid hormonal shifts are thought to contribute to mood instability. In this context, brexanolone demonstrated that targeting neurosteroid pathways could produce meaningful clinical improvement. This was significant not only for that specific condition, but also for the broader understanding of depression as a disorder that can emerge from hormonal and stress-related dysregulation, not solely from neurotransmitter imbalance.
Zuranolone, a newer oral agent, extends this concept into a more practical treatment format. Its development reflects a broader effort to integrate neurosteroid-based mechanisms into mainstream psychiatric care. While its long-term role is still being defined, it illustrates how treatment strategies are expanding to include systems that regulate emotional tone and resilience, rather than focusing exclusively on mood elevation. What distinguishes this approach from both traditional antidepressants and glutamate-based therapies is its emphasis on restoring equilibrium rather than inducing rapid change or gradual modulation. It targets the underlying instability in stress-response systems, which may contribute to persistent symptoms even when other neurotransmitter systems are addressed.
Taken together, neuroactive steroids reinforce the idea that depression is not a single-pathway disorder. It can be approached through multiple biological entry points, including plasticity, excitation, and stress regulation. This diversity of mechanisms supports a more flexible and individualized understanding of treatment, where different interventions may be appropriate depending on how the condition manifests at the level of brain systems.
The New Targets of Depression Treatment beyond Neurotransmitters
As research continues to move away from a narrow focus on serotonin and other monoamines, a broader picture of depression is emerging. The condition is increasingly understood not as a single biochemical deficit, but as a disturbance across multiple systems that regulate adaptation, timing, and integration. This shift is reflected in the growing range of therapeutic targets that extend beyond traditional neurotransmitter models.
One important direction involves treating neuroplasticity itself as a primary target. Rather than viewing plasticity as a downstream effect of treatment, it is now considered a central mechanism that can be directly influenced. This has led to interest in compounds and interventions that enhance the brain’s capacity to reorganize, adapt, and form new patterns of activity, particularly in individuals whose neural systems have become rigid under chronic stress. Another area of development focuses on brain circuit dynamics. Advances in neuroimaging and computational modeling have made it possible to study how different regions of the brain interact over time. Depression is associated with altered connectivity in networks involved in emotional regulation, attention, and self-referential processing. New approaches aim to modulate these networks more precisely, either pharmacologically or through combined strategies that integrate biological and behavioral interventions.
There is also increasing attention to circadian and sleep-related systems. Disruptions in sleep architecture and biological rhythms are common in depression and may play a causal role in symptom persistence. Interventions that target these systems are being explored not only as supportive measures, but as potential core treatments, reflecting the idea that mood regulation is closely tied to the timing and coordination of physiological processes. In parallel, the field is moving toward more individualized models of treatment. Instead of applying the same class of medication across heterogeneous patient groups, there is growing interest in identifying biological or clinical markers that can guide intervention choices. This approach, often described as precision psychiatry, aims to match treatments to specific patterns of dysfunction rather than to diagnostic categories alone.
Taken together, these developments indicate a transition from single-target pharmacology to a multi-dimensional understanding of depression. The focus is no longer limited to correcting one pathway, but to influencing a system that includes plasticity, network function, stress regulation, and temporal organization. This broader perspective does not replace earlier models entirely, but it situates them within a more complex framework that better reflects the variability of the condition and the diversity of possible interventions.
Conclusion
By 2026, depression can no longer be adequately explained as a single neurotransmitter imbalance. The long-standing focus on serotonin helped structure treatment, but it also limited how the condition was understood. What has emerged instead is a broader model in which depression is seen as a disturbance of adaptation, regulation, and neural flexibility. This shift is evident in the mechanisms of newer treatments. While traditional antidepressants modulate monoamine signaling and rely on gradual downstream effects, newer approaches target plasticity, circuit function, and stress systems more directly. The difference is not only pharmacological, but conceptual. Treatment is no longer about correcting a static deficit, but about restoring the brain’s ability to adjust and reorganize.
At the same time, earlier therapies remain relevant. Serotonergic medications continue to be effective for many patients, but they are now understood as one pathway among several, rather than the central explanation for all antidepressant effects. This allows for a more flexible approach, where different mechanisms can be considered depending on the clinical picture. The broader implication is that depression is increasingly viewed as a condition of reduced adaptability. Neural systems become less responsive and more constrained, and treatment aims to restore their capacity for change. This helps explain why newer interventions can act more rapidly or differently, by engaging the underlying mechanisms of adaptation more directly.
In this context, antidepressants are no longer defined by serotonin alone. They are part of a wider strategy focused on restoring functional balance across interconnected systems, reflecting a more complex and more accurate understanding of how depression works.
References
- Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2024). Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology, 49, 10–27. https://doi.org/10.1038/s41386-023-01629-w
- Patterson, R., Marwaha, S., Braun, J. D., Hantsoo, L., Han, V. X., & Payne, J. L. (2024). Novel neurosteroid therapeutics for post-partum depression: Perspectives on clinical trials, program development, active research, and future directions. Neuropsychopharmacology, 49, 140–154. https://doi.org/10.1038/s41386-023-01721-1
- Ahmad, A., Hussain, S., Shah, M. H., Baloch, Z. Q., Ahmad, S., Hameed, A., Hasan, M. M., & Ahmad, S. (2024). Zuranolone for treatment of major depressive disorder: A systematic review and meta-analysis. Frontiers in Neuroscience, 18, 1361692. https://doi.org/10.3389/fnins.2024.1361692